--- title: "Bard PowerPort Lawsuit: Implantable Port Device Failure Claims" url: https://www.masstortmarketingagency.com/blogs/bard-powerport-lawsuit canonical: https://www.masstortmarketingagency.com/blogs/bard-powerport-lawsuit published: 2026-01-12 modified: 2026-01-12 author: name: Tarun role: Founder, Mass Tort Agency publisher: name: Mass Tort Agency url: https://www.masstortmarketingagency.com description: | A litigation guide for personal injury attorneys handling Bard PowerPort implantable port catheter failure claims — device defect science (barium sulfate degradation, polyurethane fatigue), FDA MAUDE adverse event data, MDL proceedings, qualifying criteria, legal theories, and case valuation against C.R. Bard and Becton Dickinson. keywords: - Bard PowerPort lawsuit - implantable port catheter failure - catheter fracture and migration - Becton Dickinson litigation - medical device mass tort - 510(k) preemption license: | Cite freely with attribution to Mass Tort Agency. Verbatim quoting permitted with citation back to the canonical URL. --- # Bard PowerPort lawsuit: implantable port device failure claims > **Quick answer.** The Bard PowerPort is an implantable port catheter > system made by C.R. Bard — acquired by Becton Dickinson in 2017 for > approximately $24 billion. Plaintiffs allege design and manufacturing > defects causing catheter fracture, migration of fragments to the > heart and lungs, thrombosis, and infection. The FDA's MAUDE database > contains thousands of adverse event reports; the device was cleared > through the 510(k) pathway as a Class II device, which weakens > federal preemption defenses under Medtronic v. Lohr (1996). Federal > cases are consolidated in an MDL with bellwether selection underway; > no global settlement exists yet, and the analogous IVC filter > litigation produced outcomes from tens of thousands to several > million dollars per case. Key figures: **1000s** of MAUDE adverse reports · **$24B** BD acquisition of Bard · **510(k)** clearance pathway · **MDL** federal consolidation. ## Understanding the Bard PowerPort device and its intended use The Bard PowerPort is an implantable port catheter system manufactured by C.R. Bard, Inc., now a subsidiary of Becton, Dickinson and Company (BD). The device is surgically placed beneath the skin, typically in the chest, to provide long-term venous access: a small titanium or plastic reservoir (the port) connects to a thin, flexible catheter threaded into a large central vein, usually the superior vena cava. Ports are most common in oncology, where chemotherapy patients need reliable venous access over months or years; they are also used for long-term antibiotics, total parenteral nutrition, and frequent transfusions. The PowerPort's distinguishing feature is its "power-injectable" designation — designed to withstand the higher pressures of contrast-enhanced CT scans — a marketed advantage that is now under scrutiny as a contributing factor to the device failures driving the litigation. ## The scope of Bard PowerPort device failures ### Catheter fracture and breakage The most commonly reported failure mode. The thin polyurethane or silicone catheter can develop stress fractures where it connects to the port body or where it passes between the clavicle and first rib ("pinch-off syndrome"). A fractured distal fragment can embolize — breaking free and migrating through the venous system to the heart or lungs. ### Catheter migration to heart and lungs Migrated fragments can lodge in the right atrium, right ventricle, or pulmonary arteries, creating life-threatening emergencies: cardiac arrhythmia, cardiac perforation, cardiac tamponade, and pulmonary embolism. Retrieval typically requires interventional radiology or open-heart surgery. ### Thrombosis and blood clot formation PowerPort devices have been linked to elevated risk of deep vein thrombosis and catheter-related thrombosis, which can result in pulmonary embolism, superior vena cava syndrome, or post-thrombotic syndrome with chronic disability. ### Infection and sepsis Bacterial colonization can cause pocket infections, bacteremia, sepsis, and endocarditis. Cancer patients with chemotherapy-compromised immune systems are particularly vulnerable. | Failure Mode | Mechanism | Potential Consequences | |---|---|---| | Catheter fracture | Stress cracking, pinch-off syndrome | Fragment embolization | | Migration | Fragment travels via venous system | Cardiac perforation, tamponade | | Thrombosis | Platelet adhesion, improper positioning | DVT, pulmonary embolism | | Infection | Bacterial colonization of device | Sepsis, endocarditis | | Embolism | Air or particulate from device degradation | Stroke, MI, sudden death | ## The science behind Bard PowerPort design defects ### Barium sulfate degradation A critical defect allegation involves barium sulfate used as a radiopaque filler so the catheter is visible on X-ray. Plaintiff experts contend barium sulfate particles create stress concentration points in the polymer matrix; body fluids penetrate these micro-defects, causing hydrolytic degradation that weakens the catheter wall — accelerated by the alkaline pH of blood and the mechanical stresses of movement, breathing, and the cardiac cycle. ### Polyurethane material vulnerabilities The polyurethane catheter is subject to documented in-vivo degradation mechanisms: environmental stress cracking (ESC), metal-ion oxidation (MIO), and calcification. Plaintiffs allege Bard knew or should have known, and that alternative materials such as silicone offered superior biostability. ### Connector and hub design flaws The catheter-to-port junction is a critical stress point. Expert analysis of failed devices has identified consistent fracture patterns at or near the connector hub — suggesting a design-level problem rather than patient-specific factors. ## FDA adverse event reports and regulatory history The FDA's Manufacturer and User Facility Device Experience (MAUDE) database contains thousands of adverse event reports for the Bard PowerPort and similar devices, documenting catheter fractures, migrations, infections, and thrombotic events spanning more than a decade — valuable evidence of manufacturer notice. The PowerPort is a Class II device cleared through 510(k) premarket notification rather than the more rigorous PMA process; plaintiffs argue this allowed market entry without adequate testing. Key regulatory milestones include multiple lot-specific recalls for manufacturing defects, FDA warning letters to Bard facilities for quality system violations, and post-market surveillance showing failure rates exceeding manufacturer predictions. Attorneys should obtain complete FDA correspondence through FOIA requests. ## MDL status and litigation landscape Bard PowerPort cases are consolidated for pretrial proceedings in multidistrict litigation centralized by the Judicial Panel on Multidistrict Litigation (JPML). The MDL court has established lead counsel, a plaintiffs' steering committee, and discovery committees; bellwether cases have been selected to test claim theories before juries, providing data points for potential global settlement negotiations. Some plaintiffs have filed in state courts where product liability law, time to trial, or jury pools are more favorable — attorneys should weigh MDL participation versus state filing per client. ## Legal theories in Bard PowerPort cases - **Design defect:** risks outweigh benefits under risk-utility or consumer-expectations tests; degradation-prone materials and inadequate connector design - **Manufacturing defect:** specific units departed from intended design; FDA recall data and inspection reports document deviations - **Failure to warn:** inadequate disclosure of failure risks; under the learned intermediary doctrine the duty runs to the implanting physician - **Negligence:** failure of reasonable care in design, manufacture, testing, and post-market surveillance - **Breach of warranty:** marketing claims about durability, safety, and power-injectable capability - **Punitive damages:** evidence Bard knew about failure risks and prioritized profits over patient safety, where state law permits ## Qualifying criteria for Bard PowerPort claims 1. **Device identification.** The claimant must have had a Bard PowerPort specifically — confirmed via operative reports, implant cards, hospital records, or device tracking databases — and distinguished from ports by AngioDynamics, Teleflex, or Cook Medical. 2. **Documented complications.** Catheter fracture or breakage, migration confirmed by imaging, device-related infection requiring treatment, DVT or pulmonary embolism, surgical removal or revision, cardiac perforation or tamponade, or other serious complications requiring hospitalization. 3. **Medical record documentation.** Imaging showing fracture or migration, operative reports from removal, pathology reports from explanted devices, and ER/hospitalization records. ## Settlement data and case valuations | Injury tier | Injury type | Projected value range | |---|---|---| | Highest | Death, permanent cardiac injury, open-heart surgery | Highest settlement values | | Mid | Catheter migration requiring retrieval, serious infection, DVT | Substantial values | | Lower | Device malfunction, surgical replacement without major injury | Moderate values | No global settlement has been reached yet. The closest analog — IVC filter litigation, which involved similar migration and device-failure issues — produced settlements and verdicts ranging from tens of thousands to several million dollars per case. ## Building a strong case: evidence and discovery - **Device preservation:** preserve explanted devices for biomedical engineering analysis of failure mode - **Medical record acquisition:** implanting facility, complication treatment records, treating physicians, imaging centers - **Expert retention:** biomedical engineer (design defect), interventional radiologist (clinical consequences), hematologist/infectious disease specialist (thrombosis or sepsis), economist (future damages) - **MAUDE database review:** adverse event reports demonstrating manufacturer notice - **FOIA requests:** complete FDA correspondence on recalls, warning letters, and surveillance data ## The role of Becton Dickinson in the litigation BD acquired C.R. Bard in 2017 for approximately $24 billion, assuming Bard's liabilities including PowerPort product claims. BD's annual revenue exceeds $19 billion, with insurance coverage and litigation reserves providing a deep pool for judgments or settlements. The acquisition also raises post-acquisition conduct questions — if BD continued selling PowerPort devices despite knowledge of safety issues, plaintiffs may argue independent negligence by BD. ## Preemption defense and why it fails in PowerPort cases The preemption defense is significantly weaker for 510(k)-cleared devices than for PMA-approved devices. The Supreme Court's decision in *Medtronic v. Lohr* (1996) held that the 510(k) process does not impose device-specific federal requirements that preempt state law claims. Because the Bard PowerPort was cleared through 510(k), state law product liability claims are generally not preempted. ## Cross-referencing related practice areas Bard PowerPort cases fit firms with medical device litigation experience; related diversification areas include [hernia mesh](https://www.masstortmarketingagency.com/mass-tort-leads/hernia-mesh), [hair relaxer cancer](https://www.masstortmarketingagency.com/mass-tort-leads/hair-relaxer), and [Ozempic gastroparesis](https://www.masstortmarketingagency.com/mass-tort-leads/ozempic). Pre-qualified PowerPort claimants are available at https://www.masstortmarketingagency.com/mass-tort-leads/bard-powerport. ## Frequently asked questions ### What is the Bard PowerPort lawsuit about? Claims that implantable port catheter devices manufactured by C.R. Bard (now part of Becton Dickinson) are defectively designed and manufactured, leading to catheter fractures, migration of fragments to the heart and lungs, blood clots, infections, and other serious injuries — and that Bard knew about these risks and failed to adequately warn patients and providers. ### Who qualifies for a Bard PowerPort lawsuit? Individuals who had a Bard PowerPort implanted and experienced device-related complications such as catheter fracture, migration, infection, blood clots, embolism, or surgical removal. Medical-record documentation of both the specific Bard PowerPort device and the complications is essential. ### How much are Bard PowerPort cases worth? No global settlement has been established yet. Individual valuations may range from tens of thousands of dollars for less severe complications to potentially hundreds of thousands or more for catheter migration requiring surgical retrieval, permanent injury, or death. ### Is there a deadline to file a Bard PowerPort lawsuit? Statutes of limitations vary by state; most jurisdictions apply a discovery rule starting when the plaintiff knew or should have known of the injury and its connection to the device. Individuals with PowerPort complications should consult an attorney promptly. ### What is the current status of the Bard PowerPort MDL? Active pretrial proceedings: discovery is ongoing and bellwether case selection is underway. The MDL consolidates federal cases nationwide; attorneys should monitor developments as litigation progresses toward bellwether trials and settlement discussions. ### Can I still file a claim if my device has not yet failed? Generally, a viable claim requires an actual injury. A functioning PowerPort without complications typically does not present a ripe claim, though future complications should prompt immediate attorney consultation. Medical monitoring claims may be available in some jurisdictions. ### How do Bard PowerPort cases differ from other medical device lawsuits? They share similarities with hernia mesh litigation but involve unique issues: the catheter's interaction with the cardiovascular system, specific degradation mechanisms of port catheter materials, and a particularly vulnerable patient population (often cancer patients). The potential for catastrophic injury from catheter migration distinguishes these cases. ### What role does Becton Dickinson play in the litigation? BD acquired C.R. Bard in 2017 for approximately $24 billion and assumed Bard's liabilities, including PowerPort product claims. BD's annual revenue exceeds $19 billion, providing confidence that successful claims will result in collectible judgments or settlements.